FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097778142> ?p ?o ?g. }

• W2097778142 endingPage "662" @default.
• W2097778142 startingPage "658" @default.
• W2097778142 abstract "Background : B-cell prolymphocytic leukemias or T-cell prolymphocytic leukemias are aggressive variants of chronic lymphoid leukemias. The small studies conducted to date have shown median survival durations of approximately 3 years for patients who have B-cell prolymphocytic leukemia and 7.5 months for those who have T-cell prolymphocytic leukemia, compared with about 8 years for patients who have chronic lymphocytic leukemia. In chronic lymphocytic leukemia, chemotherapy consisting of alkylating agents such as cyclophosphamide and chlorambucil combined with prednisone has achieved overall response rates of 50% to 70%, but this regimen has resulted in response rates of less than 25% in prolymphocytic leukemia. Pentostatin (2'-deoxycoformycin; DCF) is a purine analogue that has shown activity in treatment of chronic lymphoid malignancies. Purpose : This prospective phase II trial by the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer was performed to assess the activity and toxicity of DCF in prolymphocytic leukemia. Methods : Twenty patients with B-cell or T-cell prolymphocytic leukemia were given DCF at a dosage of 4 mg/m 2 intravenously once a week for 3 weeks, then every other week for three doses. Patients who had at least partial response received maintenance therapy once a month for a maximum of 6 months. Fourteen patients had B-cell prolymphocytic leukemia, and six had T-cell prolymphocytic leukemia, as evidenced by morphologic and immunologic criteria; three were previously untreated, eight had been given one or two chemotherapeutic regimens, and nine had been given more than two. Results : One patient died of an unknown cause during the first 6 weeks of treatment, and one died of disseminated toxoplasmosis during the period of maintenance therapy, 5 months after achieving partial remission. Nine (45% response rate) of the 20 patients achieved partial remission, including seven (50%) of 14 with B-cell prolymphocytic leukemia and two (33%) of six with T-cell prolymphocytic leukemia. The median duration of response was 9 months (range, 2–30 months); for patients with B-cell prolymphocytic leukemia, the median remission duration was 12 months. No complete remission was observed. Toxic effects included nausea and vomiting (30%), infections (30%), and transient increase in liver enzymes (35%) and increatinine (20%) levels. Eight patients experienced thrombocytopenia, the major hematologic toxic effect; four had grade 3 or 4 toxic effects. Conclusion : DCF is active in prolymphocytic leukemia, even as salvage therapy in patients who had received multiple prior chemotherapeutic regimens. Implications : Trials using DCF or other purine analogues alone or in combination with standard chemotherapeutic agents in front-line or salvage therapy are warranted to improve the prognosis of patients with prolymphocytic leukemia. [J Natl Cancer Inst 85:658-662, 1993]" @default.
• W2097778142 created "2016-06-24" @default.
• W2097778142 creator A5002972322 @default.
• W2097778142 creator A5014535165 @default.
• W2097778142 creator A5035003166 @default.
• W2097778142 creator A5039285562 @default.
• W2097778142 creator A5048647000 @default.
• W2097778142 creator A5059878458 @default.
• W2097778142 creator A5067574718 @default.
• W2097778142 creator A5070752127 @default.
• W2097778142 creator A5072201297 @default.
• W2097778142 creator A5076329357 @default.
• W2097778142 creator A5078885918 @default.
• W2097778142 creator A5079852624 @default.
• W2097778142 creator A5089395073 @default.
• W2097778142 creator A5091433332 @default.
• W2097778142 date "1993-04-21" @default.
• W2097778142 modified "2023-09-26" @default.
• W2097778142 title "Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group" @default.
• W2097778142 doi "https://doi.org/10.1093/jnci/85.8.658" @default.
• W2097778142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8468724" @default.
• W2097778142 hasPublicationYear "1993" @default.
• W2097778142 type Work @default.
• W2097778142 sameAs 2097778142 @default.
• W2097778142 citedByCount "65" @default.
• W2097778142 countsByYear W20977781422012 @default.
• W2097778142 countsByYear W20977781422013 @default.
• W2097778142 countsByYear W20977781422015 @default.
• W2097778142 countsByYear W20977781422016 @default.
• W2097778142 countsByYear W20977781422017 @default.
• W2097778142 countsByYear W20977781422018 @default.
• W2097778142 countsByYear W20977781422019 @default.
• W2097778142 countsByYear W20977781422020 @default.
• W2097778142 countsByYear W20977781422021 @default.
• W2097778142 countsByYear W20977781422022 @default.
• W2097778142 crossrefType "journal-article" @default.
• W2097778142 hasAuthorship W2097778142A5002972322 @default.
• W2097778142 hasAuthorship W2097778142A5014535165 @default.
• W2097778142 hasAuthorship W2097778142A5035003166 @default.
• W2097778142 hasAuthorship W2097778142A5039285562 @default.
• W2097778142 hasAuthorship W2097778142A5048647000 @default.
• W2097778142 hasAuthorship W2097778142A5059878458 @default.
• W2097778142 hasAuthorship W2097778142A5067574718 @default.
• W2097778142 hasAuthorship W2097778142A5070752127 @default.
• W2097778142 hasAuthorship W2097778142A5072201297 @default.
• W2097778142 hasAuthorship W2097778142A5076329357 @default.
• W2097778142 hasAuthorship W2097778142A5078885918 @default.
• W2097778142 hasAuthorship W2097778142A5079852624 @default.
• W2097778142 hasAuthorship W2097778142A5089395073 @default.
• W2097778142 hasAuthorship W2097778142A5091433332 @default.
• W2097778142 hasConcept C126322002 @default.
• W2097778142 hasConcept C143998085 @default.
• W2097778142 hasConcept C203014093 @default.
• W2097778142 hasConcept C2775952470 @default.
• W2097778142 hasConcept C2775983024 @default.
• W2097778142 hasConcept C2776694085 @default.
• W2097778142 hasConcept C2776755627 @default.
• W2097778142 hasConcept C2776991684 @default.
• W2097778142 hasConcept C2777866208 @default.
• W2097778142 hasConcept C2777938653 @default.
• W2097778142 hasConcept C2778461978 @default.
• W2097778142 hasConcept C2779263901 @default.
• W2097778142 hasConcept C2779338263 @default.
• W2097778142 hasConcept C2780483514 @default.
• W2097778142 hasConcept C2780653079 @default.
• W2097778142 hasConcept C2910277799 @default.
• W2097778142 hasConcept C34628245 @default.
• W2097778142 hasConcept C71924100 @default.
• W2097778142 hasConcept C90924648 @default.
• W2097778142 hasConceptScore W2097778142C126322002 @default.
• W2097778142 hasConceptScore W2097778142C143998085 @default.
• W2097778142 hasConceptScore W2097778142C203014093 @default.
• W2097778142 hasConceptScore W2097778142C2775952470 @default.
• W2097778142 hasConceptScore W2097778142C2775983024 @default.
• W2097778142 hasConceptScore W2097778142C2776694085 @default.
• W2097778142 hasConceptScore W2097778142C2776755627 @default.
• W2097778142 hasConceptScore W2097778142C2776991684 @default.
• W2097778142 hasConceptScore W2097778142C2777866208 @default.
• W2097778142 hasConceptScore W2097778142C2777938653 @default.
• W2097778142 hasConceptScore W2097778142C2778461978 @default.
• W2097778142 hasConceptScore W2097778142C2779263901 @default.
• W2097778142 hasConceptScore W2097778142C2779338263 @default.
• W2097778142 hasConceptScore W2097778142C2780483514 @default.
• W2097778142 hasConceptScore W2097778142C2780653079 @default.
• W2097778142 hasConceptScore W2097778142C2910277799 @default.
• W2097778142 hasConceptScore W2097778142C34628245 @default.
• W2097778142 hasConceptScore W2097778142C71924100 @default.
• W2097778142 hasConceptScore W2097778142C90924648 @default.
• W2097778142 hasIssue "8" @default.
• W2097778142 hasLocation W20977781421 @default.
• W2097778142 hasLocation W20977781422 @default.
• W2097778142 hasOpenAccess W2097778142 @default.
• W2097778142 hasPrimaryLocation W20977781421 @default.
• W2097778142 hasRelatedWork W100087907 @default.
• W2097778142 hasRelatedWork W1976010943 @default.
• W2097778142 hasRelatedWork W2015931113 @default.
• W2097778142 hasRelatedWork W2097778142 @default.
• W2097778142 hasRelatedWork W2152184958 @default.

• next